Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Axitinib Accord, axitinib, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Loqtorzi, toripalimab, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Champix, varenicline, Date of authorisation: 25/09/2006, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Nilotinib Accord, nilotinib, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Rukobia, fostemsavir, Date of authorisation: 04/02/2021, Revision: 6, Status: Authorised

Union Product Database

Human medicines European public assessment report (EPAR): Rezzayo, rezafungin, Date of authorisation: 22/12/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Dectova, zanamivir, Date of authorisation: 26/04/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Ryjunea, atropine sulfate, Date of authorisation: 02/06/2025, Status: Authorised